PriceTargets.com logo

Humana - HUM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $300.50
  • Forecasted Upside: 21.61%
  • Number of Analysts: 25
  • Breakdown:
  • 0 Sell Ratings
  • 19 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$247.10 As of 12/20/2024 06:40 PM ET
▲ +11.32 (4.80%)

This chart shows the closing price for HUM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Humana Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HUM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HUM

Analyst Price Target is $300.50
▲ +21.61% Upside Potential
This price target is based on 25 analysts offering 12 month price targets for Humana in the last 3 months. The average price target is $300.50, with a high forecast of $400.00 and a low forecast of $250.00. The average price target represents a 21.61% upside from the last price of $247.10.

This chart shows the closing price for HUM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 25 investment analysts is to hold stock in Humana. This rating has held steady since March 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 12 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 12 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 19 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 19 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 19 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/17/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$288.00 ➝ $301.00
11/6/2024Bank of AmericaUpgradeUnderperform ➝ Neutral$247.00 ➝ $308.00
11/4/2024TD CowenBoost TargetHold ➝ Hold$261.00 ➝ $268.00
11/4/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$387.00 ➝ $290.00
10/31/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$250.00 ➝ $253.00
10/11/2024Truist FinancialLower TargetHold ➝ Hold$400.00 ➝ $260.00
10/11/2024KeyCorpInitiated CoverageSector Weight
10/10/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$364.00 ➝ $250.00
10/9/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$250.00 ➝ $250.00
10/8/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$400.00 ➝ $265.00
10/8/2024Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$308.00
10/7/2024TD CowenDowngradeBuy ➝ Hold$402.00 ➝ $261.00
10/7/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$519.00 ➝ $253.00
10/4/2024UBS GroupLower TargetNeutral ➝ Neutral$380.00 ➝ $250.00
10/3/2024Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$349.00 ➝ $250.00
10/3/2024Piper SandlerDowngradeOverweight ➝ Neutral$392.00 ➝ $274.00
10/3/2024OppenheimerLower TargetOutperform ➝ Outperform$400.00 ➝ $280.00
10/2/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
10/2/2024Bank of AmericaDowngradeNeutral ➝ Underperform$376.00 ➝ $247.00
10/2/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$400.00 ➝ $250.00
10/2/2024StephensDowngradeOverweight ➝ Equal Weight$400.00 ➝ $250.00
10/1/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$395.00 ➝ $395.00
9/20/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$395.00 ➝ $395.00
9/10/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$395.00 ➝ $395.00
9/5/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$385.00 ➝ $400.00
8/21/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$332.00 ➝ $396.00
8/19/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$395.00 ➝ $395.00
8/2/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$341.00 ➝ $349.00
8/1/2024OppenheimerBoost TargetOutperform ➝ Outperform$370.00 ➝ $400.00
7/24/2024TD CowenBoost TargetBuy ➝ Buy$396.00 ➝ $407.00
7/23/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$360.00 ➝ $360.00
7/15/2024Truist FinancialBoost TargetHold ➝ Hold$355.00 ➝ $400.00
6/26/2024Piper SandlerInitiated CoverageOverweight$392.00
6/24/2024Morgan StanleyInitiated CoverageEqual Weight$374.00
6/12/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$360.00 ➝ $360.00
5/30/2024Baird R WUpgradeHold
5/30/2024Robert W. BairdInitiated CoverageNeutral$374.00
5/20/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$342.00 ➝ $376.00
4/25/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$415.00 ➝ $353.00
4/25/2024Cantor FitzgeraldLower TargetNeutral ➝ Neutral$391.00 ➝ $360.00
4/25/2024UBS GroupLower TargetNeutral ➝ Neutral$334.00 ➝ $326.00
4/25/2024OppenheimerLower TargetOutperform ➝ Outperform$415.00 ➝ $370.00
4/22/2024Jefferies Financial GroupLower TargetBuy ➝ Buy$411.00 ➝ $381.00
4/10/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$391.00
4/8/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$413.00 ➝ $350.00
4/4/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$391.00
4/3/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$450.00 ➝ $385.00
4/2/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$356.00 ➝ $310.00
4/2/2024TD CowenLower TargetBuy ➝ Buy$427.00 ➝ $396.00
4/2/2024Bank of AmericaReiterated RatingBuy ➝ Neutral$470.00 ➝ $342.00
3/22/2024Raymond JamesInitiated CoverageMarket Perform
3/13/2024ArgusDowngradeBuy ➝ Hold
3/6/2024BarclaysInitiated CoverageEqual Weight$356.00
1/30/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$465.00 ➝ $413.00
1/26/2024MizuhoLower TargetBuy ➝ Buy$550.00 ➝ $400.00
1/26/2024StephensLower TargetOverweight ➝ Overweight$550.00 ➝ $430.00
1/26/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral$597.00 ➝ $391.00
1/26/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$507.00 ➝ $415.00
1/26/2024UBS GroupReiterated RatingBuy ➝ Neutral$530.00 ➝ $370.00
1/26/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$515.00 ➝ $450.00
1/25/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$595.00 ➝ $360.00
1/19/2024Truist FinancialReiterated RatingHold ➝ Hold$550.00
1/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$597.00
1/19/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$595.00 ➝ $515.00
1/19/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$599.00 ➝ $507.00
1/17/2024OppenheimerReiterated RatingOutperform ➝ Outperform$630.00
12/12/2023ArgusUpgradeHold ➝ Buy$550.00
11/21/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$597.00
11/17/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$593.00 ➝ $575.00
11/2/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$597.00
11/2/2023StephensLower TargetOverweight ➝ Overweight$575.00 ➝ $570.00
11/2/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$594.00 ➝ $599.00
10/10/2023Sanford C. BernsteinLower Target$599.00 ➝ $579.00
10/9/2023Jefferies Financial GroupBoost TargetBuy ➝ Buy$580.00 ➝ $586.00
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$597.00
8/30/2023Morgan StanleyLower TargetOverweight ➝ Overweight$637.00 ➝ $624.00
8/15/2023TD CowenLower TargetOutperform ➝ Outperform$616.00 ➝ $613.00
8/8/2023Sanford C. BernsteinBoost TargetMarket Perform ➝ Market Perform$568.00 ➝ $599.00
8/7/2023Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$468.00 ➝ $628.00
8/3/2023StephensBoost TargetOverweight ➝ Overweight$555.00 ➝ $560.00
8/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$637.00 ➝ $594.00
8/3/2023Truist FinancialBoost TargetHold ➝ Hold$530.00 ➝ $550.00
7/14/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$637.00
7/13/2023Wells Fargo & CompanyLower Target$610.00 ➝ $541.00
7/11/2023MizuhoLower Target$615.00 ➝ $550.00
7/7/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$576.00 ➝ $540.00
6/23/2023ArgusDowngradeBuy ➝ Hold
6/20/2023Truist FinancialLower Target$590.00 ➝ $530.00
6/19/2023BarclaysLower Target$620.00 ➝ $585.00
5/30/2023JPMorgan Chase & Co.Lower Target$625.00 ➝ $576.00
4/27/2023Deutsche Bank AktiengesellschaftBoost Target$562.00 ➝ $568.00
4/27/2023SVB SecuritiesLower Target$640.00 ➝ $600.00
4/20/2023Cantor FitzgeraldInitiated CoverageOverweight$597.00
4/13/2023Truist FinancialBoost TargetHold$560.00 ➝ $590.00
4/11/2023Morgan StanleyBoost TargetOverweight$620.00 ➝ $637.00
2/28/2023Deutsche Bank AktiengesellschaftLower TargetBuy$575.00 ➝ $562.00
2/7/2023Truist FinancialLower TargetHold$580.00 ➝ $560.00
2/6/2023CowenLower TargetOutperform$647.00 ➝ $581.00
2/6/2023Credit Suisse GroupLower TargetOutperform$635.00 ➝ $575.00
2/3/2023StephensLower TargetOverweight$625.00 ➝ $590.00
2/2/2023UBS GroupLower TargetBuy$645.00 ➝ $620.00
1/6/2023JPMorgan Chase & Co.Lower TargetOverweight$630.00 ➝ $625.00
12/13/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$575.00 ➝ $652.00
11/10/2022MizuhoBoost TargetBuy$529.00 ➝ $615.00
11/8/2022Wells Fargo & CompanyBoost Target$558.00 ➝ $610.00
11/7/2022CowenBoost Target$547.00 ➝ $647.00
11/7/2022CowenBoost Target$547.00 ➝ $647.00
11/3/2022The Goldman Sachs GroupBoost TargetNeutral$522.00 ➝ $575.00
11/3/2022Leerink PartnersBoost TargetOutperform$540.00 ➝ $640.00
11/3/2022Truist FinancialBoost Target$570.00 ➝ $650.00
11/3/2022Royal Bank of CanadaBoost TargetOutperform$560.00 ➝ $637.00
11/3/2022Credit Suisse GroupBoost TargetOutperform$548.00 ➝ $635.00
10/31/2022Morgan StanleyBoost TargetOverweight$549.00 ➝ $620.00
10/26/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$514.00 ➝ $576.00
9/20/2022Royal Bank of CanadaBoost TargetOutperform$541.00 ➝ $544.00
9/20/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$494.00 ➝ $549.00
9/16/2022Truist FinancialBoost TargetHold$550.00 ➝ $570.00
9/16/2022OppenheimerBoost TargetOutperform$520.00 ➝ $550.00
8/9/2022CowenBoost Target$547.00
8/2/2022Morgan StanleyBoost TargetEqual Weight$453.00 ➝ $494.00
7/28/2022Leerink PartnersBoost TargetOutperform$535.00 ➝ $540.00
7/28/2022Deutsche Bank AktiengesellschaftBoost Target$450.00 ➝ $514.00
7/28/2022OppenheimerBoost TargetOutperform$510.00 ➝ $520.00
7/19/2022Credit Suisse GroupSet Target$548.00
7/14/2022Truist FinancialBoost TargetHold$490.00 ➝ $550.00
6/16/2022Loop CapitalInitiated CoverageBuy$510.00
5/26/2022Sanford C. BernsteinInitiated CoverageMarket Perform$480.00 ➝ $506.00
5/25/2022Wells Fargo & CompanyBoost TargetOverweight$512.00 ➝ $514.00
4/28/2022Wells Fargo & CompanyBoost Target$491.00 ➝ $512.00
4/13/2022UBS GroupUpgradeNeutral ➝ Buy$486.00 ➝ $520.00
4/7/2022Truist FinancialBoost Target$460.00 ➝ $490.00
3/9/2022Morgan StanleyBoost TargetEqual Weight$410.00 ➝ $436.00
2/3/2022Deutsche Bank AktiengesellschaftBoost Target$418.00 ➝ $435.00
2/3/2022Leerink PartnersLower TargetOutperform$528.00 ➝ $525.00
1/11/2022Sanford C. BernsteinLower Target$470.00 ➝ $431.00
1/7/2022MizuhoReiterated RatingBuy$500.00
1/7/2022UBS GroupReiterated RatingHold$486.00
1/7/2022BMO Capital MarketsLower Target$490.00 ➝ $415.00
1/7/2022Wells Fargo & CompanyLower Target$529.00 ➝ $452.00
1/7/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$476.00 ➝ $418.00
1/7/2022Morgan StanleyLower TargetEqual Weight$530.00 ➝ $410.00
1/7/2022BarclaysLower TargetOverweight$540.00 ➝ $490.00
1/6/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$492.00 ➝ $529.00
1/5/2022Truist FinancialBoost TargetHold ➝ Hold$500.00 ➝ $520.00
12/16/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$559.00 ➝ $530.00
12/14/2021The Goldman Sachs GroupInitiated CoverageNeutral$472.00
11/10/2021MizuhoBoost TargetBuy$480.00 ➝ $500.00
11/9/2021Deutsche Bank AktiengesellschaftBoost TargetHold$427.00 ➝ $456.00
11/9/2021CitigroupBoost TargetBuy$510.00 ➝ $528.00
11/4/2021Bank of AmericaBoost TargetBuy$505.00 ➝ $530.00
11/4/2021Morgan StanleyBoost TargetOverweight$513.00 ➝ $559.00
11/4/2021OppenheimerBoost TargetOutperform$480.00 ➝ $510.00
11/4/2021Credit Suisse GroupBoost TargetOutperform$500.00 ➝ $513.00
11/4/2021Leerink PartnersBoost TargetOutperform$494.00 ➝ $528.00
11/4/2021Royal Bank of CanadaBoost TargetOutperform$479.00 ➝ $525.00
11/4/2021BarclaysBoost TargetOverweight$500.00 ➝ $540.00
9/27/2021Leerink PartnersInitiated CoverageOutperform$494.00
9/9/2021CowenInitiated CoverageOutperform$479.00
9/9/2021BarclaysInitiated CoverageOverweight$500.00
8/31/2021Morgan StanleyBoost TargetOverweight$500.00 ➝ $513.00
7/9/2021Seaport Res PtnReiterated RatingNeutral
7/9/2021JPMorgan Chase & Co.Boost TargetOverweight$440.00 ➝ $514.00
5/24/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$472.00
5/18/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$472.00
4/29/2021CitigroupBoost Target$496.00 ➝ $510.00
4/29/2021OppenheimerBoost TargetOutperform$460.00 ➝ $480.00
4/29/2021MizuhoBoost TargetBuy$462.00 ➝ $480.00
1/6/2021ArgusBoost TargetBuy$430.00 ➝ $450.00
1/4/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$429.00 ➝ $479.00
11/30/2020Leerink PartnersLower TargetSell ➝ Outperform$505.00 ➝ $500.00
11/4/2020Smith Barney CitigroupBoost Target$469.00 ➝ $496.00
11/4/2020Credit Suisse GroupBoost TargetOutperform$423.00 ➝ $465.00
11/4/2020OppenheimerBoost TargetOutperform$440.00 ➝ $460.00
11/4/2020StephensBoost TargetOverweight$450.00 ➝ $490.00
10/13/2020Truist FinancialBoost Target$455.00 ➝ $475.00
10/1/2020Sanford C. BernsteinInitiated CoverageMarket Perform$459.00
10/1/2020Piper SandlerBoost TargetOverweight$473.00 ➝ $495.00
9/10/2020Deutsche Bank AktiengesellschaftBoost TargetHold$397.00 ➝ $431.00
8/18/2020JPMorgan Chase & Co.Boost TargetOverweight$394.00 ➝ $452.00
8/17/2020Royal Bank of CanadaBoost TargetSector Perform$388.00 ➝ $420.00
8/10/2020StephensBoost TargetOverweight$433.00 ➝ $450.00
8/7/2020MizuhoBoost TargetBuy$420.00 ➝ $462.00
8/6/2020Credit Suisse GroupReiterated RatingBuy
8/6/2020Piper SandlerBoost TargetOverweight$442.00 ➝ $473.00
8/6/2020OppenheimerBoost TargetOutperform$425.00 ➝ $440.00
8/6/2020Leerink PartnersBoost TargetOutperform$465.00 ➝ $496.00
7/1/2020Leerink PartnersInitiated CoverageOutperform$465.00
6/18/2020Deutsche Bank AktiengesellschaftLower TargetHold$421.00 ➝ $397.00
6/17/2020Cantor FitzgeraldBoost Target$405.00 ➝ $410.00
6/16/2020CowenReiterated RatingOutperform ➝ Market Perform$410.00
6/5/2020The Goldman Sachs GroupInitiated CoverageBuy$510.00
5/21/2020SunTrust BanksBoost TargetHold$400.00 ➝ $440.00
5/4/2020MizuhoBoost TargetBuy$405.00 ➝ $420.00
4/30/2020CSFBBoost TargetOutperform$400.00 ➝ $423.00
4/30/2020Credit Suisse GroupBoost TargetOutperform$400.00 ➝ $423.00
4/30/2020CitigroupBoost TargetBuy$424.00 ➝ $435.00
4/30/2020Morgan StanleyBoost TargetOverweight$375.00 ➝ $500.00
4/30/2020OppenheimerBoost TargetOutperform$400.00 ➝ $425.00
4/13/2020Morgan StanleyBoost TargetOverweight$343.00 ➝ $375.00
3/29/2020BarclaysReiterated RatingBuy
3/27/2020Morgan StanleyLower TargetOverweight$460.00 ➝ $343.00
2/19/2020Royal Bank of CanadaReiterated RatingHold$370.00
2/18/2020Deutsche Bank AktiengesellschaftBoost TargetHold$363.00 ➝ $433.00
2/14/2020MizuhoReiterated RatingBuy$405.00
2/6/2020Morgan StanleyBoost TargetOverweight$457.00 ➝ $460.00
2/6/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$319.00 ➝ $363.00
2/6/2020MizuhoBoost TargetBuy$400.00 ➝ $405.00
2/5/2020Cantor FitzgeraldBoost TargetOverweight$345.00 ➝ $400.00
1/27/2020The Goldman Sachs GroupReiterated RatingBuy$425.00
1/23/2020UBS GroupBoost TargetNeutral$321.00 ➝ $406.00
1/8/2020Credit Suisse GroupBoost TargetOutperform$378.00 ➝ $400.00
1/3/2020JPMorgan Chase & Co.Boost TargetOverweight$437.00 ➝ $448.00
1/3/2020The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$425.00 ➝ $425.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.07 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 32 very positive mentions
  • 37 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 30 very positive mentions
  • 60 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 26 very positive mentions
  • 69 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 37 very positive mentions
  • 67 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 31 very positive mentions
  • 31 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 35 very positive mentions
  • 56 positive mentions
  • 19 negative mentions
  • 5 very negative mentions
Mentions as of
10/22/2024
  • 50 very positive mentions
  • 53 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 60 very positive mentions
  • 31 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 60 very positive mentions
  • 31 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Humana logo
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Read More

Today's Range

Now: $247.10
Low: $234.66
High: $252.54

50 Day Range

MA: $273.79
Low: $233.89
High: $304.18

52 Week Range

Now: $247.10
Low: $213.31
High: $475.00

Volume

4,223,134 shs

Average Volume

1,877,840 shs

Market Capitalization

$29.75 billion

P/E Ratio

21.89

Dividend Yield

1.48%

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Humana?

The following sell-side analysts have issued reports on Humana in the last twelve months: Argus, Baird R W, Bank of America Co., Barclays PLC, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stephens, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for HUM.

What is the current price target for Humana?

0 Wall Street analysts have set twelve-month price targets for Humana in the last year. Their average twelve-month price target is $300.50, suggesting a possible upside of 21.6%. Mizuho has the highest price target set, predicting HUM will reach $400.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $250.00 for Humana in the next year.
View the latest price targets for HUM.

What is the current consensus analyst rating for Humana?

Humana currently has 19 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HUM, but not buy more shares or sell existing shares.
View the latest ratings for HUM.

What other companies compete with Humana?

Other companies that are similar to Humana include Elevance Health, The Cigna Group, Centene, Molina Healthcare and UnitedHealth Group. Learn More about companies similar to Humana.

How do I contact Humana's investor relations team?

Humana's physical mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider's listed phone number is (502) 580-1000 and its investor relations email address is [email protected]. The official website for Humana is www.humana.com. Learn More about contacing Humana investor relations.